Outcome of Board Meeting

November 4, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Outcome of Board Meeting Ref.: Disclosures under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir / Madam, The Board of Directors (“the Board”) at their meeting held today i.e. November 4, 2026, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter / half year ended on September 30, 2026. In this regard, please find enclosed the following: 1. the unaudited financial results (standalone and consolidated) for the quarter / half year ended on September 30, 2026, reviewed by the Audit Committee and taken on record by the Board pursuant to regulation 33 of the Listing Regulations. 2. the limited review reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company (“Deloitte”) certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter / half year ended on September 30, 2026, pursuant to regulation 33 of the Listing Regulations. The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed for trading till Friday, November 6, 2026, and shall reopen on and from Monday, November 9, 2026, for the Directors and Designated Persons of the Company. The financial results and limited review reports will be available on the website of the Company at www.zyduslife.com. The Board meeting commenced at 10:50 a.m. and concluded at 12:10 p.m. Please receive the information and disclosures in order. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Deloitte Chartered Accountants 19th floor, Shapath-V S.G. Highway Haskins & Sells LLP Ahmedabad-380 015 Gujarat, India Tel: +91 79 6682 7300 Fax: +91 79 6682 7400 INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM STANDALONE FINANCIAL RES ULT S TO THE BOARD OF DIRECTORS OF ZYDUS LIFESCIENCES LIMITED 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of ZYDUS LIFESCIENCES LIMITED ("the Company"), for the quarter and half year ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations; including the manner in which it is to be disclosed, or that it contains any material misstatement. For Deloitte Haskins & Sells LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018) Kartikeya Raval Partner Place: Ahmedabad (Membership No. 106189) Date: November 04, 2026 UDIN: 261.0 61~gW(lWS HJ" 6 S.90 Page 1 of 1 Regd. Office: One International Center, Tower 3, 32nd floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 zyd Zydus lifesciences Limited ~.11fi:::::t ... dlot.if, Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej-Gandhinagar Highway, Ahmedabad -382481 Tel. No.: ( +91-79) 4804 0000 Website: www.zyduslife.com CIN : L24230GJ1995PLC025878 Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended September 30 2026 INR Million Juarter ended • Half Year ended Year ended 30/09/2026 30/06/2026 30/09/2025 30/09/2026 30/09/2025 31/03/2026 Sr. No. Particulars (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income a Revenue from operations i Sale of products 33,623 27,235 28,088 60,858 53,046 110,764 ii Other operating revenues 1197 1487 624 2,684 1,549 4 076 iii Total revenue from operations 34,820 28,722 28,712 63,542 54,595 114,840 b Other income (Refer Note-3) 1,646 1,237 5,415 2,883 6,986 16,675 C Total income 36,466 29,959 34,127 66,425 61,581 131,515 2 Expenses a Cost of materials consumed 9,865 8,615 8,908 18,480 17,445 35,307 b Purchases of stock-in-trade 1,326 1,982 445 3,308 1,006 1,977 C Changes in inventories of work-in-progress, finished goods and stock-in-trade (585) (2,167) (923) (2,752) (983) (1,516) d Employee benefits expense 5,544 5,614 4,687 11,158 9,559 19,662 e Finance costs 1,014 1,031 1,138 2,045 2,514 4,829 f Depreciation and amortisation expense 1,554 1,519 1,360 3,073 2,660 5,612 g Other expenses 9,487 9,203 8,034 18,690 14,515 32,443 h Net (gain) on foreign currency transactions (1 379) (395) (3,958) (1 774) (4,320) (12 287) i Total expenses 26 826 25 402 19,691 52 228 42,396 86,027 3 Profit before exceptional items and tax (1-2) 9,640 4,557 14,436 14,197 19,185 45,488 4 Exceptional item (Refer Note-4) 19 - 19 - 1,669 5 Profit before tax (3-4) 9,621 4,557 14,436 14,178 19,185 43,819 6 Tax expenses (Refer Note-5) a Current tax 2,492 1,177 2,817 3,669 3,713 8,998 b Deferred tax (16) 06) 53 (32) 59 (777) C Total tax expenses 2 476 1 161 2 870 3 637 3 772 8,221 7 Net Profit for the period/ year (5-6) 7,145 3,396 11,566 10,541 15,413 35,598 8 Other Comprehensive Income (OCI) a Items that will not be reclassified to profit or loss (216) 213 151 (3) 149 408 b Income tax effect on above items 33 (3) 11 30 23 (121) Total Other Comprehensive Income (183) 210 162 27 172 287 9 Total Comprehensive Income (7 +8) 6,962 3,606 11,728 10,568 15,585 35,885 10 Paid-up equity share capital (Face value Re. 1/-) (Refer Note-8) 998 998 1,006 998 1,006 1,006 11 Other equity 235,711 12 Earnings per share (not annualised for the quarter and half year) a Basic (INR) 7.15 3.38 11.49 10.53 15.32 35.38 b Diluted (INR) 7.15 3.38 11.49 10.53 15.32 35.38 Notes: [1] The above financial results were reviewed and recommended by the Audit Committee and then [Showing first 8,000 characters — download PDF for full document]